Effects of multiple doses of Albiglutide on the pharmacokinetics, Pharmacodynamics, and safety of Digoxin, Warfarin, or a low-dose oral contraceptive

Postgraduate Medicine

Volumn 124, Issue 6, 2012, Pages 55-72

  Bush, Mark ^a   Scott, Rhona ^b   Watanalumlerd, Prapoch ^c   Zhi, Hui ^a   Lewis, Eric ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Pharmaceutical Product Development   (United States)

Author keywords

Albiglutide; Contraceptive; Digoxin; Interaction; Warfarin

Indexed keywords

ALBIGLUTIDE; DIGOXIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; WARFARIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; ETHINYLESTRADIOL; GLUCAGON LIKE PEPTIDE 1; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ANXIETY; APPETITE; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CONSTIPATION; DEFECATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLATULENCE; FOLLICULITIS; HEADACHE; HUMAN; INJECTION SITE REACTION; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; METRORRHAGIA; NAUSEA; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOKINETICS; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; VAGINA CANDIDIASIS; VOMITING; ADOLESCENT; ADULT; DRUG INTERACTION; FEMALE; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL; DIGOXIN; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NORETHINDRONE; WARFARIN; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875798188     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.11.2613     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Diabetes Report Card 2012. http://www.cdc.gov/diabetes/pubs/pdf/DiabetesReportCard.pdf. Accessed October 22, 2012.
2. Liebl A, Mata M, Eschwège E; ODE-2 Advisory Board. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia. 2002;45(7):S23-S28.
3. Saydah SH, Fradkin J, Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335-342.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258): 405-412.
5. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
6. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719-2725.
7. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-520.
8. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126-1131.
9. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2005.
10. Victoza [package insert]. Princeton, NJ: Novo Nordisk; 2010.
11. Byetta [summary of product characteristics]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/ human/000698/WC500051845.pdf Accessed June 18, 2012.
12. Victoza [summary of product characteristics]. http://www.glucagon.com/pdfs/VictozaPIEU.pdf Accessed June 18, 2012.
13. Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2010.
14. Bydureon [summary of product characteristics]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf. Accessed June 18, 2012.
15. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;10:CD006423.
16. Rosenstock J, Stewart MW. Albiglutide. Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drugs Fut. 2010;35:701-712.
17. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32(10):1880-1886.
18. Matthews JE, Stewart MW, De Boever EH, et al; Albiglutide Study Group. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12): 4810-4817.
19. Fonarow GC. The management of the diabetic patient with prior cardiovascular events. Rev Cardiovasc Med. 2003;4(suppl 6):S38-S49.
20. Lanoxin [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.
21. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109(24):2959-2964.
22. Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.
23. Hewick DS, McEwen J. Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man. J Pharm Pharmacol. 1973;25(6):458-465.
24. Eble JN, West BD, Link KP A comparison of the isomers of warfarin. Biochem Pharmacol. 1966;15:1003-1006.
25. Hirsh J, Dal en J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 suppl 1):8S-21S.
26. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
27. Diabetes Atlas, 3rd ed. http://www.diabetesatlas.org/sites/default/files/IDF%20Diabetes%20 Atlas-2007%20%283rd%20edition%29.pdf Accessed May 2, 2011.
28. Goldzieher JW, de la Peña A, Chenault CB, Cervantes A. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins. Am J Obstet Gynecol. 1975;122(5): 625-636.
29. Guengerich FP Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol. 1988;33(5):500-508.
30. Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005;45(9):1032-1037.
31. Soon D, Kothare PA, Linnebjerg H, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006;46(10):1179-1187.
32. Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide-a once-daily GLP-1 analog-does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol. 2011;51(12):1696-1703.
33. World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 1983;687:81.